Scarica l'app Stockscreener
2.98
3.11%
0.09
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché SONN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.89
Aprire:
$2.88
Volume 24 ore:
45,387
Relative Volume:
0.11
Capitalizzazione di mercato:
$2.50M
Reddito:
$129.20K
Utile/perdita netta:
$-14.46M
Rapporto P/E:
-0.0461
EPS:
-64.68
Flusso di cassa netto:
$-18.52M
1 W Prestazione:
-1.32%
1M Prestazione:
-51.15%
6M Prestazione:
-78.59%
1 anno Prestazione:
-73.01%
Intervallo 1D:
$2.88
$3.00
Intervallo di 1 settimana:
$2.50
$3.50
Portata 52W:
$2.50
$18.72
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
Nome
Sonnet Biotherapeutics Holdings Inc
Settore
Industria
Telefono
609-375-2227
Indirizzo
100 OVERLOOK CENTER, PRINCETON, NJ
Confronta SONN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| SONN | 2.98 | 2.50M | 129.20K | -14.46M | -18.52M | -64.68 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Sonnet Biotherapeutics Holdings Inc Borsa (SONN) Ultime notizie
Sonnet BioTherapeutics Holdings (STU:H3D) Change In Receiva - GuruFocus.com
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment - GlobeNewswire
Sonnet BioTherapeutics Secures Crucial Patent for Novel Cancer Immunotherapy Pipeline | SONN Stock News - StockTitan
Sonnet BioTherapeutics (NASDAQ: SONN) Announces Issuance of U.S. Patent for Novel Immunotherapeutic Drug Candidates - Defense World
Sonnet BioTherapeutics secures US patent covering two drug candidates - Pharmaceutical Technology
Sonnet BioTherapeutics secures patent for cancer drug candidates By Investing.com - Investing.com Australia
SONN stock touches 52-week high at $9.9 amid market optimism - Investing.com Australia
Sonnet BioTherapeutics Prices of $5.0 Million Underwritten Public Offering - citybiz
Sonnet BioTherapeutics Announces Pricing of $5.0 Million - GlobeNewswire
Sonnet BioTherapeutics sets $5 million stock offering - Investing.com India
Sonnet BioTherapeutics sets $5 million stock offering By Investing.com - Investing.com UK
Sonnet BioTherapeutics Raises $5M in Stock Offering with Warrant Coverage | SONN Stock News - StockTitan
Sonnet BioTherapeutics secures patent for cancer drug candidates - Investing.com India
U.S. Stock market: SONN(+86.46%), DataChat(+50.28%), Cytek Biosciences(+30.51%) among the top gainers during early trading - Business Upturn
Sonnet BioTherapeutics Secures Patent for Cancer Drugs - TipRanks
Sonnet BioTherapeutics Announces Issuance of U.S. Patent - GlobeNewswire
Sonnet BioTherapeutics Secures Key Patent for Novel Cancer Immunotherapy Drugs | SONN Stock News - StockTitan
Sonnet stock tumbles 22% in wake of proposed offering filing - MSN
(SONN) On The My Stocks Page - Stock Traders Daily
When (SONN) Moves Investors should Listen - Stock Traders Daily
Sonnet BioTherapeutics (SONN) Stock Surges After Regaining Nasdaq Compliance - Stocks Telegraph
Sonnet BioTherapeutics Maintains Nasdaq Listing Compliance - TipRanks
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq - GlobeNewswire
SONN (Sonnet BioTherapeutics Holdings) Capex-to-Operating-C - GuruFocus.com
Sonnet BioTherapeutics Enters into Licensing Agreement with Alkem Laboratories for DPN in India - Chemical Industry Digest
Alkem Labs inks pact with Sonnet BioTherapeutics to develop, commercialise drug candidate for diabetic... - Medical Dialogues
Alkem Labs partners with Sonnet BioTherapeutics to develop drug candidate for diabetic peripheral neuropathy in India - BSI bureau
Alkem Labs enters into licensing agreement with Sonnet BioTherapeutics for its diabetic peripheral neuropathy drug in India - The Financial Express
Alkem Laboratories enters into a licensing agreement with US-based Sonnet BioTherapeutics - Equity Bulls
Alkem inks licensing pact with Sonnet BioTherapeutics for drug to treat diabetic neuropathy - Press Trust of India
Sonnet BioTherapeutics’ Strategic Deal to Develop DPN Treatment - Yahoo Finance
Alkem Licenses Drug for Diabetic Neuropathy in India - Rediffmail
Alkem and Sonnet BioTherapeutics Team Up for Diabetic Neuropathy Treatment - Devdiscourse
Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India - The Manila Times
Sonnet BioTherapeutics, Alkem enter licensing agreement for SON-080 - TipRanks
SONN stock touches 52-week low at $4.8 amid market challenges By Investing.com - Investing.com South Africa
SONN stock touches 52-week low at $4.8 amid market challenges - Investing.com India
Sonnet BioTherapeutics receives funding through NJEDA, Australia tax programs - TipRanks
Sonnet BioTherapeutics secures tax credit approval By Investing.com - Investing.com Australia
Sonnet BioTherapeutics secures tax credit approval - Investing.com India
Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs - ForexTV.com
Sonnet BioTherapeutics to Receive Non-Dilutive Funding - GlobeNewswire
Sonnet BioTherapeutics launches CEO Corner platform - Investing.com
Sonnet BioTherapeutics enacts reverse stock split By Investing.com - Investing.com Australia
Sonnet Biotherapeutics Holdings Inc Azioni (SONN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):